



BioLayer Corporation Limited

04 April 2007

BioLayer coatings used in locally developed tests for heart disease/diabetes

Materials science company BioLayer Corporation (ASX:BLS) today announced it has started working with Cardinal Bioresearch, an assay development company affiliated with the University of Queensland.

Cardinal is developing multiplex tests for cardiovascular and diabetes research based on the Luminex platform which allows up to 100 different tests to be simultaneously performed on a single blood sample, enabling highly time efficient and cost effective testing.

Using Cardinal's tests clinical researchers hope to find new biomarkers that identify patients at high risk of heart disease and diabetes earlier in the course of their disease, thus improving the chance of a better outcome.

The same biomarkers can also be used by clinicians to help monitor their patient's weight loss or response to therapy post diagnosis.

As part of the agreement BioLayer has used its Mix&Go™ coating to attach a range of antibodies to the Luminex beads used in Cardinal's tests.

"Having licensed our technology to other Luminex users we are very familiar with the format used by Cardinal" said David Beins, BioLayer's Managing Director and CEO. "It's great to see our Mix&Go™ beads being used right here in Queensland to improve the health outcomes of Queenslanders" he added.

"Cardinal Bioresearch is delighted to be working with BioLayer to develop these new tests for heart disease and diabetes risk" said John Cardinal, Supervising Scientist at Royal Brisbane Hospital and manager of Cardinal Bioresearch. "Obviously in this day and age there is a huge need for tests to be performed quickly and cheaply. BioLayer coatings not only help meet these criteria but have also assisted in making our tests extremely sensitive and reproducible" he continued.

BioLayer Corporation is an Australian material sciences company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and bioseparations. BioLayer's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. In the case of immunoassay this results in dramatically improved performance like better sensitivity, and cost savings like batch-to-batch reproducibility. In bioseparations it means a totally synthetic and robust surface that specifically and reversibly binds any target protein. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.bio-layer.com.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com